Ghent University Academic Bibliography

1 – 10 of 15

show: 10
|
sort: year (new to old)

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://biblio.ugent.be/publication?embed=1&q=parent+exact+%22LANCET+ONCOLOGY%22&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

Email this snippet

«previous
1
2
next»

2014
- A1
- journalArticle
Radiotherapy for renal-cell carcinoma
Gert De Meerleer UGent, Vincent Khoo, Bernard Escudier, Steven Joniau, Alberto Bossi, Piet Ost UGent, Alberto Briganti, Valérie Fonteyne UGent, Marco Van Vulpen and Nicolaas Lumen UGent, et al. (2014) LANCET ONCOLOGY. 15(4). p.e170-e177 Mark
2013
- A1
- journalArticle
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B Vermorken, Jan Stoelmacher-Williams, Irina Davidenko, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey UGent, Krzysztof Skladowski and Makoto Tahara, et al. (2013) LANCET ONCOLOGY. 14(8). p.697-710 Mark
- A1
- journalArticle
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean Luc Van Laethem, Hans Van Vlierberghe UGent, Jörg Trojan, Frank T Kolligs and Alan Weiss, et al. (2013) LANCET ONCOLOGY. 14(1). p.55-63 Mark
- A1
- journalArticle
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
Ahmad Awada, Agustin A Garcia, Stephen Chan, Guy HM Jerusalem, Robert E Coleman, Manon T Huizing, Aminder Mehdi, Sue M O'Reilly, John T Hamm and Peter J Barrett-Lee, et al. (2013) LANCET ONCOLOGY. 14(12). p.1216-1225 Mark
- A1
- journalArticle
Radiotherapy capacity in Europe
Cai Grau, Josep M Borras, Julian Malicki, Ben Slotman, Peter Dunscombe, Mary Coffey, Donal Hollywood, Ferran Guedea, Chiara Gasparotto and Yolande Lievens UGent (2013) LANCET ONCOLOGY. 14(6). p.E196-E198 Mark
- A1
- journalArticle
Surgery or radiotherapy for early-stage lung cancer: a potential comparison bias
Paul E Van Schil and Jan Van Meerbeeck UGent (2013) LANCET ONCOLOGY. 14(10). p.e390-e390 Mark
2012
- A1
- journalArticle
Mediastinal staging of lung cancer: novel concepts
Kurt Tournoy UGent, Steven M Keller and Jouke T Annema (2012) LANCET ONCOLOGY. 13(5). p.e221-e229 Mark
2011
- A1
- journalArticle
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
Bertrand Coiffier, Evgenii A Osmanov, XiaoNan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner UGent, Simon Rule, Adriana Teixeira, Jan Walewski and Sven de Vos, et al. (2011) LANCET ONCOLOGY. 12(8). p.773-784 Mark
2009
- A1
- journalArticle
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzoferro, Josep M. Llovet, Rosalbo Miceli, Sherrie Bhoori, Marcello Schiavo, Luigi Mariani, Tiziona Camerini, Sasan Roayaie, Myron E. Schwartz and Gian Luca Grazi, et al. (2009) LANCET ONCOLOGY. 10(1). p.35-43 Mark
- A1
- journalArticle
Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment
Wim Ceelen UGent and Marc Bracke UGent (2009) LANCET ONCOLOGY. 10(1). p.72-79 Mark

«previous
1
2
next»